

Methodology article

Open Access

Building pathway clusters from Random Forests classification using class votes

Herbert Pang¹ and Hongyu Zhao*^{1,2}

Address: ¹Division of Biostatistics, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520, USA and ²Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, USA

Email: Herbert Pang - herbert.pang@yale.edu; Hongyu Zhao* - hongyu.zhao@yale.edu

* Corresponding author

Published: 6 February 2008

Received: 6 August 2007

BMC Bioinformatics 2008, 9:87 doi:10.1186/1471-2105-9-87

Accepted: 6 February 2008

This article is available from: <http://www.biomedcentral.com/1471-2105/9/87>

© 2008 Pang and Zhao; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Recent years have seen the development of various pathway-based methods for the analysis of microarray gene expression data. These approaches have the potential to bring biological insights into microarray studies. A variety of methods have been proposed to construct networks using gene expression data. Because individual pathways do not act in isolation, it is important to understand how different pathways coordinate to perform cellular functions. However, there are no published methods describing how to build pathway clusters that are closely related to traits of interest.

Results: We propose to build pathway clusters from pathway-based classification methods. The proposed methods allow researchers to identify clusters of pathways sharing similar functions. These pathways may or may not share genes. As an illustration, our approach is applied to three human breast cancer microarray data sets. We found that our methods yielded consistent and interpretable results for these three data sets. We further investigated one of the pathway clusters found using PubMatrix. We found that informative genes in the pathway clusters do have more publications with keywords, like estrogen receptor, compared with informative genes in other top pathways. In addition, using the shortest path analysis in GeneGo's MetaCore and Human Protein Reference Database, we were able to identify the links which connect the pathways without shared genes within the pathway cluster.

Conclusion: Our proposed pathway clustering methods allow bioinformaticians and biologists to investigate how informative genes within pathways are related to each other and understand possible crosstalk between pathways in a cluster. Therefore, building pathway clusters may lead to a better understanding of molecular mechanisms affecting a trait of interest, and help generate further biological hypotheses from gene expression data.

Background

The increasing use of high-throughput microarray technologies in biological and biomedical research has motivated many novel statistical and computational approaches to analyze such data. They can be applied to

(1) identify differentially expressed genes, (2) discover subclasses through clustering, and (3) classify subjects into known classes. Although most of these methods either examine one gene at a time, i.e. single-gene based, or all the genes at the same time, a number of methods

investigate a set of genes at a time, where the gene-set information can come from various external databases, such as KEGG [1], BioCarta [2] and GenMapp [3]. These curated gene-sets or pathways from biological experiments often serve a particular cellular or physiological function. These gene-set based (or pathway-based) methods include Gene Set Enrichment Analysis (GSEA) [4], Random Forests [5], Hotelling's T^2 [6], and Significance Analysis of Microarray to gene-set analyses (SAM-GS) [7]. Although it is unlikely that one particular method will be superior to others for all the data sets, these methods seem to be able to generate biologically meaningful results for different data sets. In addition, pathway-based tests can identify more subtle changes in expression than single gene based tests [8]. Furthermore, pathway-based methods can generate biological hypotheses more effectively based on prior knowledge. These hypotheses may be readily tested using complementary approaches, e.g. proteomics and metabolomics analyses.

It is well known that different pathways do not work in isolation. In fact, each pathway is part of an overall biological network. Therefore, it is natural to ask how different pathways, or gene-sets, coordinate their activities. In the context of using gene expression data to predict a trait of interest, e.g. cancer, some pathways may function in a coherent fashion whereas others may have independent functions or effects on phenotypes. Despite the importance of this topic, there is scant literature on relating different pathways. In this paper, we propose to cluster pathways that have similar effects on the phenotype of interest. Our approach is built on our previous proposal of adopting the Random Forests approach for pathway analysis [5]. The Random Forests approach has been found to perform very well among a number of machine learning methods in pathway-based classification. To extend the Random Forests approach for pathway cluster analysis, we use class votes from Random Forests to build pathway clusters related to phenotype of interest. As detailed below in the Methods section, class votes can provide a measure of the similarity between two subjects' gene expression profiles for a given pathway. This measure can then be used to define similarities, or distances, between pathways. Based on these inferred pathway distances, we then use the Tight Clustering [9] approach to identify pathway clusters. The identification of such clusters may provide useful information for biologists to generate hypotheses on the underlying disease mechanisms. Pathway clusters may also help identify novel biomarkers for screening or serving as drug targets for combination therapy.

The rest of the paper is organized as follows. The detailed methodology is discussed in the Methods section. In the Results section, we demonstrate the usefulness of this

approach through the application of our methods to three different breast cancer microarray data sets to uncover pathway clusters that are involved in estrogen receptor (ER) status classification. We conclude the paper in the Discussion and Conclusions sections.

Methods

We first briefly review the Random Forests approach for pathway analysis [5]. Random Forests constructs many classification trees and thus the name 'forest'. For each pathway, the input data for Random Forest would be a gene expression matrix of the genes belonging to the pathway by the number of subjects in the data set. Every tree in a Random Forests is built using a deterministic algorithm and the trees are different from the ordinary tree algorithms (e.g. CART) owing to two factors. First, at each node, a best split is chosen from a random subset of the predictors rather than all of them. Second, every tree is built using a bootstrap sample of the original observations. A subject is put down a tree for classification using the input vector of gene expression for genes within a particular pathway. The tree gives a classification and decides which class this subject belongs to. In the end, the forests choose the class that gives the majority votes for each subject. The out-of-bag (OOB) data, approximately one-third of the observations, are then used to estimate the prediction accuracy. Small classification error based on genes in a given pathway would indicate the pathway as potentially interesting [5].

We can build for each pathway a Random Forest to predict an individual's phenotype based on his/her gene expression levels within this pathway. To define whether two pathways have similar effects on an individual's phenotype, we can use the pathway prediction results to define their similarities. For example, if two pathways always give the same phenotype prediction based on gene expression data in these pathways, we infer that these two pathways have similar functions. To realize this idea, we use an output from Random Forests, class votes, to define pathway distances that can be used to build pathway clusters.

Class Votes

To define class votes, for each study subject, the proportion of votes for a specific class is recorded based on the prediction results from individual trees in the Random Forest. Therefore, every pathway defines a class vote matrix of length n by k , where n is the number of samples in the study and k is the number of classes. In case of only two classes, we can use the votes of one class to represent the confidence of each individual belonging to that particular class. For example, for subject A, if we have 0.15 for class 1 and 0.85 for class 2, that means subject A has been voted to be class 2 85% of the time. Therefore, two pathways can be thought to have similar effects on the pheno-

type if the class vote matrices/vectors from these two pathways are similar.

Building Pathway Clusters

Based on class votes, we propose to use Tight Clustering to infer pathway clusters.

Tight Clustering is a robust method using re-sampling for clustering and pattern recognition [9]. It finds tight and stable clusters in a sequential manner. The K-means algorithm is applied iteratively, along with the calculations of the average co-membership matrices and similarity measures of cluster sets. When performing Tight Clustering on the class votes for a pair of pathways, the Euclidean distance between them is used. Tight Clustering does not explicitly estimate the number of clusters, but allows the user to specify the target number of Tight Clusters. It is usually infeasible to estimate the number of clusters since it is not uncommon to see figures that give clear and informative pattern for different number of clusters. For more details of the algorithm, see [9]. As mentioned in their paper, because microarray analysis is an exploratory tool to guide further biological investigations which could potentially be costly, some genes, called scattered genes in their paper, should be left out of the Tight Clusters. This is also true in the pathway-based context. Tight Clusters of class votes for pathways are found and pathways that are not related to other pathways should be left without being clustered. We varied the target number of Tight Clusters from 5 to 20 in analyzing the breast cancer data sets. Tight Clusters which contain two or more top ranked pathways with low OOB error rates are investigated further and pathway clusters are built from them. A heatmap can be used to visualize the Tight Clustering output.

Schematic diagrams of our proposed methods are given in Figures 1 and 2.

Data sets

Pathways

A total of 495 pathways were used for the analysis. These pathways are wired diagrams of a set of predefined genes and molecules from KEGG [1], BioCarta [2], and GenMapp [3] databases. Every pathway in these databases contains a set of genes that are related to some cellular, molecular and/or physiological functions from earlier experiments. These genes are then mapped to the corresponding probes IDs on the microarray chipsets. The distribution is as follows:

- (1) A total of 151 pathways were taken from KEGG, a pathway database with the majority responsible for metabolism, degradation and biosynthesis. There are also a few signal or information processing pathways and others related to human diseases and drug development.




Figure 1
A Schematic Diagram of How to Identify Clusters of Pathways. Pathway (gene sets) information from externally available database, such as KEGG, BioCarta and GenMapp is combined with gene expression from clinical studies. We perform pathway-based Random Forests classification to obtain Class Votes. We identify clusters of pathways containing pathways with low OOB error rate using Tight Clustering. We identify the clusters of pathways that are consistent among different data sets. These pathway clusters are investigated further for possible crosstalk among them.




Figure 2
Tight Clustering. A diagram illustrating Tight Clustering on Class votes.

(2) We considered 283 BioCarta pathways. Most of these pathways are related to signal transduction for human with a smaller group of metabolic pathways.

(3) The 61 GenMapp pathways we used consist of more genes per set on average. There are different types of pathways such as metabolic pathways, signal transduction pathways, gene families and subcellular components.

Microarray data

Three different breast cancer microarray data sets were used. All of these studies used Affymetrix GeneChip®, but they are of different versions. *Consort* data set was based on hgu-133 plus 2.0 with 54,613 probesets whereas the other two, *LymphNode* and *p53* data sets [10,11], were based on an older chip called hgu-133a with 22,215 probesets. *Consort* [12] data set consists of 99 breast tissue samples with clinical status of estrogen receptor. *LymphNode* data set consists of frozen tumor samples of 286 lymph-node negative patients who had not received adjuvant systematic treatment [10]. *p53* data set is a set of 251 frozen tissues that were sequenced for p53 [11].

We chose the breast cancer data sets and ER positive/negative status (ER+/ER-) to study because breast cancer has been extensively studied in the literature and tumor samples are normally classified on the basis of ER status [13]. A recent publication described a set of prognostic gene expression classifiers for ER+ breast cancer [14]. The estrogen receptor status has also been used to predict breast cancer therapy, breast cancer survival rate and estimate the risk of breast cancer [15-18]. ER+ breast cancers are usu-

ally treated with hormone therapy whereas ER- breast cancers are treated using chemotherapy. Not all breast carcinomas are responsive to the treatment though. Thus, there is an urgent need to identify novel therapeutic targets and develop new agents. Moreover, pathway crosstalk and new biological insights might help find predictive biomarkers [19].

To deal with the issue of unbalanced sample size between the ER+ and ER- groups we utilized weighted Random Forests. The *p53* data set is the most unbalanced among the three breast cancer data sets we analyzed, it has 213 in the ER+ and 38 in the ER- groups. For more details on why we chose this approach, see the discussion in the see Additional file 1, DMS1.

The above data sets are available for download from the GEO website under the accessions GSE2109, GSE3494 and GSE2034 for the *Consort*, *p53* and *LymphNode* data sets, respectively. See Table 1.

Software

The library package randomForest v4.5-18 from the R program was used in our analysis [20] for the Balanced Random Forests solution. A modified version of the original Fortran code was used to perform the Weighted Random Forests in our pathway-based context [21]. For pathway clusters visualization, Cytoscape [22] was used.

Biological Significance

We considered using GO terms based enrichment analysis, but Goeman and Bühlmann [23] pointed out that this approach may not be satisfactory and may result in false positives. Therefore, we used two alternative approaches. First, we used PubMatrix [24], a web-based application that identifies genes' citation with keywords of interest. Genes that contribute most in predicting the correct class in pathway-based classification are called informative genes [5]. We compared the informative genes defined by Random Forests classification that were obtained in the pathway cluster sets and examined whether these genes are more likely to have publications with the keywords of interest compared with informative genes from the top pathways not in the pathway cluster. Although importance measure in Random Forests could be biased [25], it is unlikely in our case since we only used normalized gene expression data and did not combine it with other cate-

Table 1: Breast cancer data sets used in this study

Data sets	Reference	n	Genes	Response type
<i>Consort</i>	INTEGEN	99	54613	ER status
<i>LymphNode</i>	[10] Wang (2005)	286	22215	ER status
<i>p53</i>	[11] Miller (2005)	251	22215	ER status

gorical data, such as sequence data described in [25]. Second, we investigated possible pathways crosstalk using GeneGo's MetaCore [26] and Human Protein Reference Database (HPRD) [27]. Shortest path analyses between a pair of genes were performed using GeneGo's MetaCore to assess how close the two genes are related to each other based on the curated database of human protein-protein, protein-DNA and protein compound interactions.

Results

Class Votes

The target number of Tight Clusters, 5, 10, 15 and 20 were chosen and the tuning parameters were as defined in the Tight Clustering manual. We found that the pathway clusters identified when the target number was 5, 10 and 15 were essentially a subset of those in the 20 Tight Clusters case. To facilitate the investigation of pathway crosstalk, we consider a larger number of Tight Clusters, i.e. 20. We considered forming 25, 30, 35 tight clusters in addition to 5, 10, 15, and 20. Most of the clusters discovered in 20 tight clusters run were rediscovered in 25, 30, and 35. Please see Additional files 2 and 3, varysize_5-10-15-20.xls and varysize_20-25-30-35.xls for more details. On page 12 of the manual for the Tight Clustering program, four sets of parameters for tight clusters of size 5, 10, 15 and 20 were suggested. Therefore, we chose 20 tight clusters. Among these 20 inferred Tight Clusters, we selected those clusters containing two or more pathways whose OOB error rates were among the top 22 lowest across all the pathways. Since we aim to pick out the top pathways with the same OOB error rates, if we had chosen the top 20 pathways, we would have missed some pathways with the same OOB error rates. Based on this criterion, the OOB error rates cut off was 15.5%, 15.5%, and 20% for

the *p53*, *LymphNode* and *Consort* data sets respectively. In each of the three data sets, three Tight Clusters were selected. These Tight Clusters are listed in Additional file 1, Table A1 for *Consort*; Table A2 for *LymphNode*; and Table A3 for *p53* data set. A2ii and A3i from Additional file 1 for *LymphNode* and *p53* data sets, respectively, highly resemble each other (Table 2). Apart from the Alzheimer's disease pathway, the other five pathways are overlapped between the *LymphNode* and *p53* data sets. A2iii, A3ii and A1i in the respective data sets are also very similar (Table 3). "Butanoate metabolism", "Propanoate metabolism" and "Valine leucine and isoleucine degradation" appear in each of the three Tight Clusters of the three different data sets. The A3iii Tight Cluster in *p53* data set is a subset of a much larger Tight Cluster A2i in *LymphNode*, see Additional file 1, Tables A2 and A3 for more details.

Pathway Clusters

We further investigate the pathway cluster (Table 2) found from the previous section. Figure 3 consists of three pathway clusters built from the overlapped pathways. It can be seen that "GATA3 participates in activating the Th2 cytokine gene pathway" and "Nitrogen Metabolism pathway" do not have any overlapping probes with the other 3 pathways. The ESR1 gene is shared among 3 pathways: "PELP1 Modulation of Estrogen Receptor Activity pathway", "CARM1 and Regulation of the Estrogen Receptor pathway", and "Downregulated of MTA 3 in ER negative Breast Tumors pathway". In addition to ESR1, the PELP1 and CARM1 pathways share the informative PELP1 gene. Genes, such as RARA, PGR, PDZK1, HSPB1, HDAC2, and MAPK3 that are not shared also show some importance in classifying subjects.

Table 2: Tight Cluster Results I

<i>LymphNode</i> (A2ii in Additional file 1)	OOB error(%)	Number of probes
BC-Pelp1_Modulation_of_Estrogen_Receptor	15.38	20
Alzheimer's_disease	17.13	23
BC-Deregulation_of_CDK5_in_Alzheimers_Disease	16.08	24
BC-Downregulated_of_MTA_3_in_ER_negative_Breast_Tumors	12.24	26
BC-GATA3_participate_in_activating_the_Th2_cytokine	11.89	33
Nitrogen_metabolism	14.34	40
<i>Gene Symbols of informative genes in this pathway cluster</i>		
MAPK3, PELP1, ESR1, PDZK1, HSPB1, CA12, GLS, IL5, JUNB, GATA3, MAP2K3, MAPT, STH, CSNK1A1		
<hr/>		
<i>p53</i> (A3i in Additional file 1)		
BC-Pelp1_Modulation_of_Estrogen_Receptor	13.94	20
BC-Downregulated_of_MTA_3_in_ER_negative_Breast_Tumors	15.54	26
BC-GATA3_participate_in_activating_the_Th2_cytokine	13.55	33
Nitrogen_metabolism	17.13	40
BC-CARM1_and_Regulation_of_the_Estrogen_Receptor	14.34	54
<i>Gene Symbols of informative genes in this pathway cluster</i>		
MAPK3, PELP1, ESR1, PDZK1, HSPB1, HDAC2, CA12, GLS, IL5, JUNB, GATA3, MAP2K3		

The bold pathways are those with low OOB error rates

Table 3: Tight Cluster Results 2

<i>LymphNode</i> (A2iii in Additional file 1)	OOB error(%)	Number of probes
beta Alanine metabolism	16.08	42
Alanine_and_aspartate_metabolism	16.78	42
Glutamate metabolism	16.08	50
Butanoate metabolism	16.08	59
Propanoate_metabolism	17.83	59
Valine leucine and isoleucine degradation	14.69	71
<i>Gene Symbols of informative genes in this pathway cluster</i> ABAT, ALDH1A3, GLUL, GMPS, HMGCL, HSD17B4, MAP3K15, MCCC2, PDHA1		
<hr/>		
<i>p53</i> (A3ii in Additional file 1)		
Alanine_and_aspartate_metabolism	17.53	42
Butanoate metabolism	15.54	59
Propanoate_metabolism	18.33	59
GM-Glycolysis_and_Gluconeogenesis	23.11	66
Valine leucine and isoleucine degradation	15.54	71
<i>Gene Symbols of informative genes in this pathway cluster</i> ABAT, ALDH1A3, HMGCL, HSD17B4, MAP3K15, MCCC2, PDHA1		
<hr/>		
<i>Consort</i> (A1i in Additional file 1)		
Glycosphingolipid_biosynthesis	23.23	34
BC-GATA3 participate in activating the Th2 cytokine	14.14	43
Butanoate metabolism	15.15	82
Propanoate_metabolism	21.21	85
Valine leucine and isoleucine degradation	17.17	25
<i>Gene Symbols of informative genes in this pathway cluster</i> ABAT, GATA3, HSD17B4, MCCC2, PRKAR1B		

The bold pathways are those with low OOB error rates

PubMatrix

To more systematically study the biological significance of the results, we looked at the publications of the top informative genes (top two genes in each pathway) with keywords, like breast cancer, estrogen receptor, and progesterone receptor, of interest. We examined the top informative genes from the pathway cluster in Table 2, which consists of 5 pathways, with two of them that do not have any overlapping probes with the rest. It is evident from PubMatrix search that the proportions of these informative genes in the pathway cluster do show a higher number of literature support compared with the informative genes outside of the pathway cluster (Table 4). This is true for the informative genes for all three data sets and more so for the *p53* data set. To assess the significance of these results, Fisher's Exact Test was performed. For breast cancer citations, the p-values were 0.149, 0.002, and 0.061 for data sets, *LymphNode*, *p53*, and *Consort*, respectively (Table 5). This indicates a significantly higher proportion of citations related to breast cancer for genes in pathway cluster of Table 2 compared to other informative genes in the top pathways for the *p53* data set. The result for *Consort* just misses the significant cutoff of 0.05, and it is not significant for the *LymphNode* data set. It was not surprising to see more significant results for estrogen

receptor citations, since we are specifically doing classification on the ER+/ER- status. All of the p-values are significant; 0.048, 0.0006, and 0.0084 for data sets *LymphNode*, *p53*, and *Consort*, respectively (Table 6).

Possible Pathway Crosstalk

From the previous section, we have seen that even though there are no overlapping genes between both "Nitrogen metabolism" and "GATA3 participate in activating Th2 cytokine genes expression" pathways with other pathways containing ESR1, they appear to form a tight pathway cluster. In order to further understand the possible crosstalk between them, we looked at HPRD and GeneGo's MetaCore. We found connections between GATA3 pathway and CARM-1 pathway from HPRD. This is illustrated in Figure 4, where the dark grey oval genes GATA and junB in GATA3 pathway interacts with PPARBP and ESR1 in CARM-1 pathway. The gene PPARBP, Peroxisome proliferator-activated receptor binding protein, is determined to be at a high level of expression and amplified in breast cancer [28]. In Figure A5 in Additional file 1, it suggests how different proteins receive signals from ESR1 and act upon HIF-1 to regulate CA12.




Figure 3
Pathway Clusters. A pathway cluster showing a total of five pathways, three of which have shared genes and two pathways do not share common genes.

Table 4: Proportion of genes showing more than the indicated number of literature support

Informative genes not in pathway cluster (Table 2) of top 22 pathways for <i>LymphNode</i>	BC	ER	PR	
≥ 1		0.44	0.33	0.20
≥ 2		0.31	0.27	0.18
≥ 5		0.24	0.20	0.09
<hr/>				
<i>LymphNode</i> (pathway cluster)	BC	ER	PR	
≥ 1		0.42	0.42	0.33
≥ 2		0.42	0.42	0.25
≥ 5		0.25	0.33	0.17
<hr/>				
Informative genes not in pathway cluster (Table 2) of top 22 pathways for <i>p53</i>	BC	ER	PR	
≥ 1		0.41	0.35	0.20
≥ 2		0.33	0.28	0.13
≥ 5		0.24	0.24	0.11
<hr/>				
<i>p53</i> (pathway cluster)	BC	ER	PR	
≥ 1		1.00	1.00	0.75
≥ 2		1.00	0.75	0.63
≥ 5		0.63	0.63	0.25
<hr/>				
Informative genes not in pathway cluster (Table 2) of top 22 pathways for <i>Consort</i>	BC	ER	PR	
≥ 1		0.50	0.22	0.16
≥ 2		0.44	0.38	0.25
≥ 5		0.34	0.28	0.13
<hr/>				
<i>Consort</i> (pathway cluster)	BC	ER	PR	
≥ 1		0.88	0.75	0.63
≥ 2		0.75	0.63	0.50
≥ 5		0.50	0.50	0.25

BC = breast cancer, ER = estrogen receptor, PR = progesterone receptor

Shortest Path Analyses

To investigate the possibility of pathway crosstalk further, we searched for the shortest path between GATA3 and CA12 with other top informative genes in the network of all links in the database of GeneGo's MetaCore. This tool assists in finding regulatory paths between two or more genes of interest. The results are shown in Tables 7 and 8. For both GATA3 and CA12, they are the genes with the least number of gene steps to the gene ESR1, with 2 and 3

steps, respectively. It further strengthens our belief that the pathways GATA3 and Nitrogen Metabolism are closely tied with the other four pathways within the pathway cluster. The number of links with a distance of two between GATA3 and ESR1 is 6, which is much larger than ESR1 and EGFR or IKBKB both with just one gene connecting between them. The gene, MUC1, connects ESR1 and EGFR. IKK-alpha is the gene which connects ESR1 and IKBKB. These two genes are a subset of the 6 between

Table 5: Breast Cancer Citations

<i>LymphNode</i>	In citation	Not in citation	p-value
Genes in pathway cluster (Table 2)	8	4	
Informative genes not in pathway cluster (Table 2) of top 22 pathways	20	25	0.149
<hr/>			
<i>p53</i>	In citation	Not in citation	p-value
Genes in pathway cluster (Table 2)	8	0	
Informative genes not in pathway cluster (Table 2) of top 22 pathways	19	27	0.002
<hr/>			
<i>Consort</i>	In citation	Not in citation	p-value
Genes in pathway cluster (Table 2)	7	1	
Informative genes not in pathway cluster (Table 2) of top 22 pathways	16	16	0.061

Table 6: Estrogen Receptor Citations

<i>LymphNode</i>	In citation	Not in citation	p-value
Genes in pathway cluster (Table 2)	8	4	
Informative genes not in pathway cluster (Table 2) of top 22 pathways	16	30	0.048
<i>p53</i>	In citation	Not in citation	p-value
Genes in pathway cluster (Table 2)	8	0	
Informative genes not in pathway cluster (Table 2) of top 22 pathways	15	30	0.0006
<i>Consort</i>	In citation	Not in citation	p-value
Genes in pathway cluster (Table 2)	6	2	
Informative genes not in pathway cluster (Table 2) of top 22 pathways	7	25	0.0084

GATA3 and ESR1. Furthermore, there are 7 literature support of genes MUC1 and HNF3-alpha [29-35] related to breast neoplasm compared to 6 (MUC1) for EGFR and none for IKBKB. In fact, EGFR is one of the genes in the Calcium Signalling pathway which also share genes with the GATA3 pathway. CA12 and ESR1 are also closely tied; CA12 is connected to ESR1 through HIF-1 and NCOA1. There are 4 literature support of genes HIF-1 and NCOA1 related to breast neoplasm [36-39]. Again, the EGFR is at the top of this chart with the same number gene steps but with 4 different paths, and two more literature support than CA12. Another gene IL6ST has two different paths and three literature support. Although, it seems that the connection between CA12 and the four pathways with ESR1 is not as strong, it is still significant relative to the majority of the top informative genes which show 4 or more gene steps.




Figure 4
Links between GATA3 and CARM1 pathways using HPRD. The connection between genes in GATA3 and CARM1 pathways using information obtained from HPRD.

Discussions

In this article, we have described a Random Forests-based approach to identify clusters of pathways sharing similar functions. Class votes measure similarity at the individual level. Using the three different breast cancer data sets to classify between estrogen receptor positive and negative status, we found that Tight Clustering for class votes yielded consistent and interpretable results. We also considered other means of measuring the similarity of class votes, such as the similarities between class votes solely by Euclidean distances, but their performance was less consistent than the methods described here. Moreover, another output, proximity matrices, for Random Forests was also investigated, but it was found to be highly correlated with the class votes (see Figures A4.). Bioinformaticians and biologists can make use of the proposed methods to discover pathway clusters, find informative genes shared between pathways and identify genes that bridge between pathways within a pathway cluster. This allows researchers to obtain results that are more closely tied to the biological mechanism of diseases and to examine pathway crosstalk.

Due to the unbalanced nature of the data sets in this study, the weighted random forests (WRF) algorithm was used. WRF seems to perform better than the alternative balanced random forests procedure. Although we are looking at ER+ vs. ER- status for the *Consort*, *p53* and *LymphNode* data sets, it is reasonable to obtain different pathway clusters from them. This is because the patients were from different clinical settings. The *Consort* data set consists of patients from a consortium of different breast cancer studies, the *p53* data set consists of patients whose tissue were sequenced for *p53* and the *LymphNode* data set only has patients with negative lymph node status.

In this article, we have also demonstrated the biological relevance of our approach using PubMatrix. The number of citations for informative genes within the pathway

Table 7: Shortest Path between GATA3 and other Genes in the Top 22 Pathways (without overlap with GATA3 pathway)

GATA3 and	Distance (gene steps)	Number of links with the shortest distance*	Genes with literature related to breast cancer*
ESR1 (in pathway cluster)	2	6 [MUC1, SMAD8, IKK-alpha, HDAC4, HNF3-alpha, GATA-1]	7
EGFR	2	1 [MUC1]	6 (subset of the 7 above)
IKBKB	2	1 [IKK-alpha]	0
IFNAR	3		
GFRA1	3		
IGF1	3		
ATP7B	3		
VAV3	3		
COX7c	3		
B3GNT6	3		
MYCL1	3		
ACACB	3		
UQCRH	3		
LYN	3		
ACTN1	3		
IL6ST	3		
STC2	4		
PDXK	4		
CFLAR	4		
BBOX1	4		
TARS	5		
SSH3	5		
NDUFA9	6		
HMGCL	6		
ABAT	6		
DAZAP2	Infinity		

*shown only for the shortest distance

Table 8: Shortest Path between CA12 and other Genes in the Top 22 Pathways (without overlap with Nitrogen Metabolism pathway)

CA12 and	Distance (gene steps)	Number of links with the shortest distance*	Genes with literature related to breast cancer*
ESR1 (in pathway cluster)	3	1 (HIF-1, NCOA1)	4
EGFR	3	4 (HIF-1 + MAPK3, Beta-catenin, STAT5B, MAPK1)	6
IL6ST	3	2 (HIF-1 + MAPK1, MPAK3)	3
COX7c	4		
IGF1R	4		
YES	4		
ACTN1	5		
PRKX	5		
VAV3	5		
ABAT	6		
HMGCL	6		
SSH3	6		
TARS	6		
ADCY9	7		
BBOX1	7		
PDXK	7		
UQCRH	7		
B3GNT6	9		
DAZAP2	Infinity		

*shown only for the shortest distance

cluster together with keywords, like estrogen receptor, is enriched compared to other informative genes of top pathways. We have illustrated the use of GeneGo and HPRD to help us understand possible crosstalk among pathway clusters. The shortest path analyses of GATA3 and CA12 show that the informative genes in pathway clusters are closer in terms of regulatory paths than those informative genes in other top pathways. Furthermore, with the aid of a network visualization tool, biologists can investigate how the informative genes are related to each other within the pathway clusters.

Conclusion

The novel methods presented in this article were able to identify pathway clusters related to outcome of interests that are biologically meaningful. Understanding how the informative genes relate and talk with each other within pathway clusters can help generate further biological hypotheses for follow-up studies. These may be tested using other "omics" technologies, such as proteomics and metabolomics. When the outcome variable is continuous, we can employ the Random Forests Regression approach [5] and easily extend what we have described in this article to the regression setting by using the predicted values from the Random Forests output.

In this paper, we have proposed one way to building pathway clusters. It might be possible to utilize output from other pathway-based methods, such as GSEA to determine the similarity in enrichment scores between two pathways and build a graph of pathway network from the calculated similarity measures. Moreover, our approach would encourage other researchers to look into new ways in building pathway clusters and bring fresh insights into microarray analysis.

Authors' contributions

HP and HZ developed this new method for building pathway clusters. HP did the programming and carried out the computational work. Both authors read and approved the manuscript.

Additional material

Additional file 1

This file contains supporting information for this paper. These include: a study of weighted random forests vs. balanced random forests, GeneGo MetaCore output and tight clusters and absolute differences results.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2105-9-87-S1.DOC>]

Additional file 2

Tight Clustering results for 5, 10, 15 and 20 tight clusters.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2105-9-87-S2.xls>]

Additional file 3

Tight Clustering results for 20, 25, 30 and 35 tight clusters.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2105-9-87-S3.xls>]

Acknowledgements

Support provided in part by National Institute of Health (NIH) grants U24 NS051869 and R01 GM59507. We thank the International Genomics Consortium (IGC) and Expression Project For Oncology (expO) for making one of the data sets available to us. We thank three anonymous reviewers for their valuable comments and suggestions. We also thank Keck Biostatistics Resource at Yale for the GeneGo's MetaCore account and Matthew Holford for providing the informatics support and access to the gene interaction database.

References

1. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M: **The KEGG resource for deciphering the genome.** *Nucleic Acids Res* 2004, **32**:D277-80.
2. **BioCarta** [<http://www.biocarta.com/>]
3. Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR: **GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways.** *Nat Genet* 2002, **31**:19-20.
4. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: **Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles.** *Proc Natl Acad Sci* 2005, **102**:15545-15550.
5. Pang H, Lin A, Holford M, Enerson BE, Lu B, Lawton MP, Floyd E, Zhao H: **Pathway analysis using random forests classification and regression.** *Bioinformatics* 2006, **22**:2028-2036.
6. Kong SW, Pu WT, Park PJ: **A multivariate approach for integrating genome-wide expression data and biological knowledge.** *Bioinformatics* 2006, **22**:2373-2380.
7. Dinu I, Potter JD, Mueller T, Liu Q, Adewale AJ, Jhangri GS, Einecke G, Famulski KS, Halloran P, Yasui Y: **Improving gene set analysis of microarray data by SAM-GS.** *BMC Bioinformatics* 2007, **8**:242.
8. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC: **PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.** *Nat Genet* 2003, **34**:267-273.
9. Tseng GC, Wong WH: **Tight clustering: A resampling-based approach for identifying stable and tight patterns in data.** *Bioinformatics* 2005, **61**:10-16.
10. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatko T, Berns EM, Atkins D, Foekens JA: **Gene-expression profiles to predict distant metastasis of lymphnode-negative primary breast cancer.** *Lancet* 2005, **365**:671-679.
11. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J: **An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.** *Proc Natl Acad Sci* 2005, **102**:13550-13555.
12. **International Genomics Consortium** [<http://www.intgen.org/>]
13. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA, Marks JR, Nevins JR: **Predicting the clinical status of**

- human breast cancer by using gene expression profiles.** *Proc Natl Acad Sci* 2001, **98**:11462-11467.
14. Teschendorff AE, Naderi A, Barbosa-Morais NL, Pinder SE, Ellis IO, Aparicio S, Brenton JD, Caldas C: **A consensus prognostic gene expression classifier for ER positive breast cancer.** *Genome Biol* 2006, **7**:R101.
 15. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM, West M, Nevins JR, Huang AT: **Gene expression predictors of breast cancer outcomes.** *Lancet* 2003, **361**:1590-1596.
 16. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE: **Risk factors for breast cancer according to estrogen and progesterone receptor status.** *J Natl Cancer Inst* 2004, **96**:218-228.
 17. Berry DA, Cirincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP: **Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.** *JAMA* 2006, **295**:1658-1667.
 18. Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe DG, Robertson JF, Aparicio S, Ellis IO, Brenton JD, Caldas C: **A gene-expression signature to predict survival in breast cancer across independent data sets.** *Oncogene* 2007, **26**:1507-16.
 19. Lupu R, Menendez JA: **Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?** *Endocrinology* 2006, **147**:4056-4066.
 20. Liaw A, Wiener M: **Classification and regression by random Forest.** *R News* 2002, **2**:18-22.
 21. **Weighted Random Forests** [http://www.stat.berkeley.edu/~breiman/RandomForests/cc_software.htm]
 22. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: **Cytoscape: a software environment for integrated models of biomolecular interaction networks.** *Genome Res* 2003, **13**:2498-2504.
 23. Goeman JJ, Bühlmann P: **Analyzing gene expression data in terms of gene sets: methodological issues.** *Bioinformatics* 2007, **23**:980-987.
 24. Becker KG, Hosack DA, Dennis G Jr, Lempicki RA, Bright TJ, Cheadle C, Engel J: **PubMatrix: a tool for multiplex literature mining.** *BMC Bioinformatics* 2003, **4**:61.
 25. Strobl C, Boulesteix AL, Zeileis A, Hothorn T: **Bias in random forest variable importance measures: illustrations, sources and a solution.** *BMC Bioinformatics* 2007, **8**:25.
 26. **GeneGo MetaCore** [<http://www.genego.com/>]
 27. Peri S, Navarro JD, Amanchy R, Kristiansen TZ, Jonnalagadda CK, Surendranath V, Niranjan V, Muthusamy B, Gandhi TK, Gronborg M, Ibarrola N, Deshpande N, Shanker K, Shivashankar HN, Rashmi BP, Ranya MA, Zhao Z, Chandrika KN, Padma N, Harsha HC, Yatish AJ, Kavitha MP, Menezes M, Choudhury DR, Suresh S, Ghosh N, Saravana R, Chandran S, Krishna S, Joy M, Anand SK, Madavan V, Joseph A, Wong GW, Schiemann WP, Constantinescu SN, Huang L, Khosravi-Far R, Steen H, Tewari M, Ghaffari S, Blobe GC, Dang CV, Garcia JG, Pevsner J, Jensen ON, Roepstorff P, Deshpande KS, Chinnaiyan AM, Hamosh A, Chakravarti A, Pandey A: **Development of human protein reference database as an initial platform for approaching systems biology in humans.** *Genome Res* 2003, **13**:2363-2371 [<http://www.hprd.org>].
 28. Zhu Y, Qi C, Jain S, Le Beau MM, Espinosa R 3rd, Atkins GB, Lazar MA, Yeldandi AV, Rao MS, Reddy JK: **Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer.** *PNAS* 1999, **96**:10848-53.
 29. Greenberg R, Barnea Y, Schneebaum S, Kashtan H, Kaplan O, Skornik Y: **Detection of hepatocyte growth factor/scatter factor receptor (c-Met) and MUC1 from the axillary fluid drainage in patients after breast cancer surgery.** *Isr Med Assoc J* 2003, **5**:649-52.
 30. Nacht M, Ferguson AT, Zhang W, Petroziello JM, Cook BP, Gao YH, Maguire S, Riley D, Coppola G, Landes GM, Madden SL, Sukumar S: **Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer.** *Cancer Res* 1999, **59**:5464-70.
 31. Diaz LK, Wiley EL, Morrow M: **Expression of epithelial mucins Muc1, Muc2, and Muc3 in ductal carcinoma in situ of the breast.** *Breast J* 2001, **7**:40-5.
 32. Vgenopoulou S, Lazaris AC, Markopoulos C, Boltetsou E, Kyriakou V, Kavantzias N, Patsouris E, Davaris PS: **Immunohistochemical evaluation of immune response in invasive ductal breast cancer of not-otherwise-specified type.** *Breast* 2003, **12**:172-8.
 33. Seregini E, Coli A, Mazzucca N, Italian Group RIA-IRMA Test, Italian Association of Nuclear Medicine: **Circulating tumour markers in breast cancer.** *Eur J Nucl Med Mol Imaging* 2004, **31**(Suppl 1):S15-22.
 34. Felton T, Harris GC, Pinder SE, Snead DR, Carter GI, Bell JA, Haines A, Kollias J, Robertson JF, Elston CW, Ellis IO: **Identification of carcinoma cells in peripheral blood samples of patients with advanced breast carcinoma using RT-PCR amplification of CK7 and MUC1.** *Breast* 2004, **13**:35-41.
 35. Williamson EA, Wolf I, O'Kelly J, Bose S, Tanosaki S, Koeffler HP: **BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1).** *Oncogene* 2006, **25**:1391-9.
 36. Kang HJ, Kim HJ, Kim SK, Barouki R, Cho CH, Khanna KK, Rosen EM, Bae I: **BRCA1 modulates xenobiotic stress-inducible gene expression by interacting with ARNT in human breast cancer cells.** *J Biol Chem* 2006, **281**:14654-62.
 37. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E: **Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.** *Cancer* 2003, **97**:1573-81.
 38. Gruber G, Greiner RH, Hlushchuk R, Aebbersold DM, Altermatt HJ, Berclaz G, Djonov V: **Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?** *Breast Cancer Res* 2004, **89**:375-833.
 39. Fleming FJ, Hill AD, McDermott EV, O'Higgins NJ, Young LS: **Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.** *J Clin Endocrinol Metab* 2004, **89**:375-83.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

